The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Ananya Mariam Rajesh·Stocktwits

Updated Oct 10, 2025 | 2:05 PM GMT-04

Add us on

AstraZeneca PLC (AZN) is reportedly set to unveil a deal with U.S. President Donald Trump about reducing drug prices.

According to a Bloomberg News report, citing sources familiar with the matter, the agreement would mark the second such partnership by a pharmaceutical company to help progress one of Trump’s central healthcare initiatives.

The report noted that the details about the pact weren’t immediately clear. The agreement is part of the Trump administration’s efforts to lower drug prices in the U.S. and to ensure that wealthy nations contribute more significantly to the cost of developing breakthrough medical innovations.

U.S.-listed shares of AstraZeneca fell nearly 1% in afternoon trading. Retail sentiment on AstraZeneca remained unchanged in the ‘neutral’ territory compared to a day ago, with message volumes at ‘low’ levels, according to data from Stocktwits.

An agreement with the British pharmaceutical giant bolsters the Trump administration’s drug pricing initiative and could prompt other firms to join the discussions to cut drug prices.

The report noted that the deal could be announced at the White House on Friday. This would follow Trump’s announcement of a deal with Pfizer (PFE) in late September, which included steep drug price cuts and also a $70 billion investment in domestic manufacturing facilities.

Trump had then said that Pfizer agreed to supply several of its most commonly used medications “at heavily discounted prices of anywhere between 50% and even 100%.”

Shares of AstraZeneca have gained over 29% this year and jumped nearly 10% in the last 12 months.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Also See: Why Did Protagonist Therapeutics Stock Soar Today?